Cystitis due to Blastoschizomyces Capitatus Successfully Treated with Fluconazole: A Case Report

Saddam Al Demour¹, Adel Alrabadi¹, Ra’ed Haddad¹, Emad Tarawneh², Faris G Bakri³

Abstract

The incidence of fungal urinary tract infections has been increasing and is usually linked with the use of systemic chemotherapy, use of immunosuppressive medications, and overuse of antibiotics. Non-candida urinary tract infections are uncommon. Blastoschizomyces capitatus is an emerging invasive infection in immunosuppressed patients. Urinary infections with this pathogen are rarely reported. Here, we present a case of a diabetic female patient with a urinary tract infection caused by this pathogen. The infection was successfully treated with fluconazole therapy.

Keywords: Blastoschizomyces capitatus, Cystitis, Diabetes, Fluconazole, Ureteric stent.

Introduction

Blastoschizomyces capitatus (B. capitatus) is a yeast-like fungus, previously known as Trichosporon capitatum and Geotrichum capitatum before being classified under the new genus (Blastoschizomyces).¹ Infections caused by B. capitatus are uncommon, and patients affected by this fungus are usually immunosuppressed.

Fungal infections of the urinary tract also typically occur in immunosuppressed patients. Most of these infections are caused by Candida albicans and non-albicans Candida species. Non-candida urinary tract infections are uncommon, and cases of cystitis due to B. capitatus infection are rarely reported.²³ Here, we report a case of cystitis due to B. capitatus in a diabetic female patient. The infection was managed effectively with fluconazole.

Case Report

A 65-year old female patient with diabetes and on oral hypoglycemic medications for the last nine years presented to clinic our hospital.

1. Department of Special Surgery, Division of Urology, Jordan University Hospital and School of Medicine, The University of Jordan, Amman, Jordan.
2. Department of Radiology, Jordan University Hospital and School of Medicine, The University of Jordan. Amman, Jordan.
3. Department of Medicine, Jordan University Hospital, Infectious Disease and Vaccine Center, and School of Medicine, The University of Jordan, Amman, Jordan.

*Correspondence should be addressed to:
Saddam Al Demour, MD, MRCS, FEBU, FACS
School of Medicine, The University of Jordan, Queen Rania Street, Amman 11942 – Jordan
P.O Box 13046
E-mail: saddamaldemour@yahoo.com
saldemour@ju.edu.jo

© 2018 DAR Publishers / The University of Jordan. All Rights Reserved.
The patient had a ureteric stent insertion for a right lower ureteric stone at another institution two years prior to her presentation to us. The ureteric stent was missed for one year before the stone, and the stent was removed. Following stent removal, the patient began to complain of frequency, urgency, urge incontinence, nocturia, and hematuria. The patient took several courses of antibiotics without benefit before presenting to us one year after the onset of those symptoms. She had never been on corticosteroids or chemotherapeutic medications.

Her physical examination was unremarkable. The urinalysis showed turbid urine with numerous white blood cells (WBCs) per high power field (HPF) and 6 to 8 red blood cells per HPF. Two midstream urine cultures were negative. Her serum WBC was 10,700/mL, and HbA1c was 8%. Tests for human immunodeficiency virus (HIV) and hepatitis B and C viruses were negative. All blood cultures were negative. Computed tomography (CT) of the urinary tract showed a thick bladder wall, with significant fat stranding around the bladder (Figure 1).

Figure 1. Computed tomography (CT) scan showing a thick bladder wall with significant fat stranding around the bladder (arrow)
Given the fact that the patient had hematuria and lower urinary tract symptoms that were not responding to antibiotics, a diagnostic cystoscopy was performed to rule out a sinister pathology. On cystoscopy, the bladder was severely inflamed with diffuse mucosal erythema, multiple punctate bleeding points, scattered white patches adherent to the mucosa, a significant amount of sloughed tissue in the bladder lumen, and patent ureteric orifices. Because these findings were suspicious for either bladder carcinoma in situ or fungal infection, transurethral resection biopsies were performed, a urine culture was collected directly from the bladder by cystoscope, and the patient was started on fluconazole intravenously.

Subsequently, the urine culture from the cystoscopy grew yeast. However, the yeast failed to change color with chrome agar. Thus, another identification test, the Remel Yeast test, was performed, identifying the yeast as *B. capitatus*. A histopathologic examination revealed severely inflamed bladder mucosa with no evidence of malignancy (Figure 2).

The patient was kept on intravenous fluconazole 400 mg/day for 21 days. During this time, the hematuria resolved, followed by gradual improvement of urgency and frequency. A repeat urine culture during treatment was negative. A follow-up urinary tract CT scan two weeks later showed improved perivesical inflammation (Figure 3).

One month after stopping fluconazole, the patient reported significant improvement and complete resolution of her symptoms. Her urine culture remained negative. One year after stopping fluconazole, the patient was still free of urinary symptoms.

Figure 2. Histopathologic examination of the bladder mucosa showing severe, chronic follicular cystitis with no evidence of malignancy
Cystitis due to Blastoschizomyces capitatus

Saddam Al Demour et al.

J Med J 2018; March: Vol. 52 (1) http://journals.ju.edu.jo/jmj

Figure 3. Follow-up computed tomography (CT) scan showing marked reduction in bladder wall thickness and residual fat stranding (arrow)

Discussion

The normal habitat of *B. capitatus* is the soil, but it can be isolated from the skin, respiratory tract, and gastrointestinal tract of healthy individuals. These organisms have previously been considered contaminants; however, infections caused by them have been increasing in recent decades. These infections have been attributed mostly to the increased use of systemic chemotherapy, increased prevalence of HIV infections, and empirical use of antifungals.

*B. capitatus* was reported to have caused severe invasive infections in immunocompromised patients, mainly those who had received chemotherapy for acute leukemia, patients on corticosteroids, patients with uncontrolled diabetes mellitus, and recipients of bone marrow transplants.

The patient in this case had severe cystitis due to *B. capitatus*. Her risk factors for *B. capitatus* infection included diabetes mellitus, overuse of antibiotics, and previous ureteric stent insertion. On cystoscopy, cystitis appeared as severe, erythematous, diffuse bladder inflammation with adherent white patches and a significant amount of sloughed tissue. This appearance resembled bladder carcinoma, especially carcinoma in situ. The patient had significant bothersome lower urinary tract symptoms that resolved after antifungal therapy, indicating that *B. capitatus* cystitis was the sole cause for her symptoms.

Treatment of *B. capitatus* is not well-established due to its rarity. Systemic or intravesical amphotericin B has been used to treat fungal urinary tract infections. Voriconazole has been reported to be effective in some cases of *B. capitatus* infection; however, the fungus was not fully eradicated in
subsequent cultures despite symptom improvement.3 Others have reported successful treatment of invasive B. capitatus infections with amphotericin B and fluconazole.9,10 In our case, the patient began to improve after a few days of empirical fluconazole therapy, so it was continued even after identifying B. capitatus. Voriconazole was not used as it was unavailable at that time. Amphotericin B was not used due to its potential nephrotoxic adverse effects. Eventually, the patient completely recovered with the use of fluconazole, and negative urine cultures after one year of follow-up indicated cure.

In conclusion, we are reporting a severe urinary tract infection caused by an unusual organism, B. capitatus. We believe this report adds to the body of literature concerning this fungal infection and highlights potential therapeutic options.

References

التهاب المثانة البولية بسبب (بالإسباني: Blastoschizomyces capitatus)

المعالجة بنجاح بواسطة الفلوكانزول

صدام الضمور١، عادل الريض١، رعد حداد٢، عماد الطاوة٢، فارس البكري٣

1- استشاري جراحة الكلى والمسالك البولية، قسم الجراحة الخاصة، مستشفى الجامعة الأردنية، كلية الطب، الجامعة الأردنية.
2- استشاري الأشعة التشخيصية والداخلية، قسم الأشعة، مستشفى الجامعة الأردنية، كلية الطب، الجامعة الأردنية.
3- استشاري الأمراض الباطنية والأمراض المعدية، قسم الأمراض الباطنية، مستشفى الجامعة الأردنية، كلية الطب، الجامعة الأردنية.

الملخص

زادت في الأونة الأخيرة نسبة حدوث الالتهابات البولية بسبب الجراثيم الفطرية، وقد يكون ذلك مرتبطة بعدة عوامل منها، استخدام العقاقير الكيميائية لمعالجة الورم السرطاني، والعقاقير المضادة للحصان المناعي، وكذلك الاستخدام المفرط للمضادات الحيوية. تعد الالتهابات الفطرية التي تسبب الجهاز البولي من غير جرثومة (candida) أمرًا غير شائع وقليل الحدوث وهناك نوع نادر من هذه الجراثيم (Бlastoschizomyces capitatus) يصيب المرضى المثبطين مناعيًا. تعتبر إصابة الجهاز البولي بـ (Blastoschizomyces capitatus) نوعًا من الفطرية نادر الحدوث والحالات المسجلة بهذا النوع قليلة. فقد قمنا بتقديم هذه الحالة لصالحة بالتهاب المثانة البولية الناجمة بسبب هذه الجراثيم النادرة لدى امرأة تعاني من مرض السكري، وقد تم علاجها بنجاح بواسطة استخدام علاج مضاد للفطرية (Fluconazole).

الكلمات الدلالة: بلاتشوشيомيس كابيتاتوس، التهاب المثانة البولية، السكري، فلوكانزول، قسطرة حالية.